Archive | October, 2019

RESI Asia Partnering Launches Monday, October 28th

24 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

The partnering platform has always been one of the main differentiators of the RESI Conference. Powered by the LSN Investor Platform, the detailed investor profiles that allow companies to book one-on-one meetings with partners who are a fit for them streamlines the process and improves the quality of the meetings that take place at RESI. The partnering platform allows attendees to filter by sector, stage of development, indication, among other factors, to find only those investors and strategic partners who are looking for technologies like theirs. Once an attendee requests a meeting, and the recipient has accepted it, the partnering platform will automatically assign a time and a table for the meeting to take place. Starting on Monday, Oct. 28th, attendees of RESI Asia will be able to take advantage of this system to book up to 16 high-quality one-on-one meetings. If you are interested in learning tips on how to make the best use of the partnering platform, here are a few articles that can help:

Confirmed RESI Asia Investors

VIVA Biotech, Shanghai, China based CRO will be the Innovation Challenge Gold Sponsor for RESI

24 Oct

By Candice He, Global Investment Strategist, LSN

After supporting the RESI Conference Series with delegates and speakers for many years, VIVA Biotech has become a Gold Sponsor of RESI Shanghai and RESI San Francisco.  At RESI, you will be able to meet with VIVA’s delegation of elite portfolio companies, and with top expert speakers representing VIVA at RESI’s panels and pitch sessions. You will also have the opportunity to meet with VIVA during RESI’s cocktail party, where VIVA will present the awards for the RESI Innovation Challenge!  Finally, RESI Shanghai attendees will also have the opportunity to take a tour of VIVA Biotech’s incubator.  We hope you will join us and our sponsors and partners at RESI Shanghai.

About VIVA Biotech

Viva Biotech’s mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Supporting RESI Conferences for years, VIVA Biotech will be the Innovation Challenge Gold Sponsor for RESI Shanghai on Nov. 12th and RESI San Francisco on Nov. 14th

Exercise for Your Brain’s Health: Interview with Prof John J. Ratey, Associate Clinical Professor of Psychiatry at Harvard Medical School

24 Oct

By Lucy Parkinson, VP of Investor Research, LSN

Continuing LSN’s series of video interviews with life science thought leaders, Dennis Ford recently sat down with John J. Ratey, Associate Clinical Professor of Psychiatry at Harvard Medical School.  John’s career has focused on the role exercise can play in treating psychiatric conditions such as ADHD, depression, anxiety, addiction, and stress.  In this 12-minute interview, John talks to Dennis about how he began to focus on this connection, even as an ever greater proportion of the population adopt sedentary lifestyles.  John explores the possibility of ‘rewilding’ society to incorporate more movement and human connections to improve our mental health, and the tantalizing possibility that ‘AI coaches’ could help us reach this goal.

Hot Investor Mandate: Multi Family Office Seeks to Invest in Promising Life Science Companies with Asia Angle

24 Oct

A multi-family office founded in 2017 has offices in multiple countries throughout Asia. The firm is jointed by 12 families and each has a minimum personal or family asset of 30 million USD. Currently, the firm has total assets under management of 34 million USD. Typical Allocations Size of the firm is around 1.5 million USD. The firm invested in 2 companies in the year 2019 and they do not have a strict limit to the number of new investments.

The firm is open to investing in general Bio-medical industries, including medical devices, healthcare IT and therapeutics. The firm has a preference for reproductive medicine and eye-related topics. Any kind of technic, device or service are welcomed under these 2 topics. Besides the topics above, the firm is currently looking for pre-clinical and phase I opportunities in therapeutic companies as well as medical devices and healthcare IT companies that are in development. Apart from the bio-medical industry, the firm also focuses on investing in E-Vehicle related startups.

The firm is looking for companies with Asia Angle, preferably Asia-based or those plan to do R&D in Asia. The firm is typically a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Firm Seeks Cross-Border Investment Opportunities with Strong Interests in Therapeutics and Digital Health

24 Oct

A Taiwan-based VC with additional offices in USA has invested primarily in Taiwanese companies, but actively considers those based in the US as well. The firm invests primarily in therapeutics and digital health. The firm looks to be an active investor, and can help those companies looking to expand to the US. The firm invests early, in seed-early stage rounds, and generally makes a first investment of between $500K-1M.

The firm primarily invests in therapeutics and digital health, although will consider investing in medical devices or diagnostics if the company is exceptional. For therapeutics technology, the firm is agnostic to indication and will invest as early as proof of concept stage, although some animal data is preferable. For digital health companies, the firm is fairly flexible with regards to stage of development and will consider most healthcare-related or IoT technologies (e.g. smart hospital applications).

The firm looks for companies with great teams, whether they are experienced entrepreneurs or not. For companies based in Taiwan, the firm prefers to lead investments and take a board seat, playing an active role after investment. For US-based companies, the firm will generally co-invest and may recommend a partner to the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Medical Device Arm of Large Chinese Pharma Seeks to Invest in and Support Commercialization of Early-Stage Life Science Companies

24 Oct

A medical device of a large Chinese pharmaceutical company has 226 affiliated companies with a total of over 8,000 employees, making over 3 billion revenue each year. The firm is interested in early-stage diagnostics, medical device and healthcare IT companies, but will also consider drugs in applicable cases.

The firm is generally interested in medical devices, diagnostics, and Digital healthcare companies with a preference for healthcare platform and CFDA approved companies. The firm will look at different stage companies that are investing in angel to pre-A, and IPO companies and provide investment consulting services to the firm

The firm invests globally but prefers companies with Chinese backgrounds. The firm strongly prefers companies with at least one Mandarin speaker in the management teams. The firm is willing to work with academic researchers or companies that are in very early stages and can provide supports in commercialization using the firm’s already-established internet platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: R&D Subsidiary of China Pharma Seeks Various Partnerships with Digital Health Technologies & Early-Stage Therapeutics Across Various Modalities

24 Oct

An R&D subsidiary of a Chinese pharmaceutical focuses on novel therapeutics. In the meantime, the firm is also responsible for sourcing global technology assets for the parent company. The firm is interested in Therapeutics and Healthcare IT opportunities. Fully funded by the parent company, the firm’s allocation size varies for the case to case, no upper limit, and in addition to investment the firm is also interested in co-development, in-licensing, and acquiring.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, CAR-T Therapy, Targeted Therapy, oncolytic virus therapy, and rare disease. Any combination of AI technology and therapeutics is preferred. For therapeutics, the firm focuses on products in pre-clinical and Phase I stage and will consider orphan indications.

The firm has no specific requirements for company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →